Creative Medical Technology Announces Its ADAPT Trial To Study Its CELZ-201 Is 85% Enrolled

Dear Fellow Shareholder: Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis ("OA"), immunotherapy, and biodefense. This progress, combined with disciplined capital allocation and expanding non-dilutive opportunities, positions the Company for durable value creation on behalf of long-term shareholders. The Company’s strategy is straightforward: Advance Olastrocel (CELZ-201) toward Phase 3 readiness in chronic lower back pain. Scale Ultrasome™, the Company’s cell-free osteoarthritis program, as a partner-ready asset. Build the CELZ-Biodefense Toxic Exposure Atlas™ into a differentiated data and discovery platform with government and strategic collaboration potential. Recent Clinical and Regulatory Milestones Olastrocel (CELZ-201) – Spine Mo...